Abstract
It has been shown that some chalcones are able to inhibit tubulin polymerization, giving cytotoxicity and destruction of tumoral vasculature. A library of 180 novel chalcone analogs has been synthesized via click chemistry and screened for their cytotoxicity and tubulin assembly inhibition. 10 out 180 click chalcones displayed low micromolar cytotoxicity but only compound Nf depicted antitubulin activity. While Nf displayed only micromolar potency this result shows click-chalcones may be anti-tubulin agents and validate this strategy to search for novel active chemical entities.
Keywords: Antitubulinic agent, Cancer, Chalcone analogs, Click chemistry, Cytotoxicity, Tubulin
Medicinal Chemistry
Title:Parallel Synthesis of “Click” Chalcones as Antitubulin Agents
Volume: 9 Issue: 4
Author(s): Maleeruk Utsintong, Alberto Massarotti, Antonio Caldarelli and Sewan Theeramunkong
Affiliation:
Keywords: Antitubulinic agent, Cancer, Chalcone analogs, Click chemistry, Cytotoxicity, Tubulin
Abstract: It has been shown that some chalcones are able to inhibit tubulin polymerization, giving cytotoxicity and destruction of tumoral vasculature. A library of 180 novel chalcone analogs has been synthesized via click chemistry and screened for their cytotoxicity and tubulin assembly inhibition. 10 out 180 click chalcones displayed low micromolar cytotoxicity but only compound Nf depicted antitubulin activity. While Nf displayed only micromolar potency this result shows click-chalcones may be anti-tubulin agents and validate this strategy to search for novel active chemical entities.
Export Options
About this article
Cite this article as:
Utsintong Maleeruk, Massarotti Alberto, Caldarelli Antonio and Theeramunkong Sewan, Parallel Synthesis of “Click” Chalcones as Antitubulin Agents, Medicinal Chemistry 2013; 9 (4) . https://dx.doi.org/10.2174/1573406411309040004
DOI https://dx.doi.org/10.2174/1573406411309040004 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Recent Advances in Enone and NO-Releasing Derivatives of Oleanolic Acid with Anti-cancer Activity
Mini-Reviews in Organic Chemistry Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets GqPCR-mediated Signalling in the Spotlight: From Visualization Towards Dissection and Quantification
Current Pharmaceutical Biotechnology MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets Cerium Oxide Nanoparticles Trigger Neuronal Survival in a Human Alzheimer Disease Model By Modulating BDNF Pathway
Current Nanoscience Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination
Anti-Cancer Agents in Medicinal Chemistry Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design New Molecular Targets in the Treatment of NSCLC
Current Pharmaceutical Design